参考文献/References:
[1] Aquino CC,Fox SH.Clinical spectrum of levodopa-induced complications[J].Mov Disord,2015,30(1):80-89.
[2] Van Gerpen JA,Kumar N,Bower JH,et al.Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County,Minnesota,1976-1990[J].Arch Neurol,2006,63(2):205-209.
[3] Pilleri M,Antonini A.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease[J].Expert Opin Drug Saf,2015,14(2):281-294.
[4] Lindgren HS,Andersson DR,Lagerkvist S,et al.L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease:temporal and quantitative relationship to the expression of dyskinesia[J].J Neurochem,2010,112(6):1465-1476.
[5] Hirano S,Asanuma K,Ma Y,et al.Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease[J].J Neurosci,2008,28(16):4201-4209.
[6] Ko JH,Lerner RP,Eidelberg D.Effects of levodopa on regional cerebral metabolism and blood flow[J].Mov Disord,2015,30(1):54-63.
[7] Fénelon G,Mahieux F,Huon R,et al.Hallucinations in parkinson's disease:prevalence,phenomenology and risk factors[J].Brain,2000,123(Pt 4):733-745.
[8] Beaulieu-Boire I,Lang AE.Behavioral effects of levodopa[J].Movement Disorders,2015,30(1,SI):90-102.
[9] Manni R,Terzaghi M,Ratti PL,et al.Hallucinations and REM sleep behaviour disorder in Parkinson's disease:dream imagery intrusions and other hypotheses[J].Conscious Cogn,2011,20(4):1021-1026.
[10] Friedman JH.Pimavanserin for the treatment of Parkinson's disease psychosis[J].Expert Opin Pharmacother,2013,14(14):1969-1975.
[11] Black KJ,Hershey T,Koller JM,et al.A possible substrate for dopamine-related changes in mood and behavior:prefrontal and limbic effects of a D3-preferring dopamine agonist[J].Proc Natl Acad Sci U S A,2002,99(26):17113-17118.
[12] Lv KL,Lang EA.Parkinson's disease[J].Lancet,2015,386(9996):896-912.
[13] Fasano A,Petrovic I.Insights into pathophysiology of punding reveal possible treatment strategies[J].Mol Psychiatry,2010,15(6):560-573.
[14] Fasano A,Ricciardi L,Pettorruso M,et al.Management of punding in Parkinson's disease:an open-label prospective study[J].J Neurol,2011,258(4):656-660.
[15] Cilia R,Siri C,Canesi M,et al.Dopamine dysregulation syndrome in Parkinson's disease:from clinical and neuropsychological characterisation to management and long-term outcome[J].J Neurol Neurosurg Psychiatry,2014,85(3):311-318.
[16] Lim SY,O'sullivan SS,Kotschet K,et al.Dopamine dysregulation syndrome,impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease[J].J Clin Neurosci,2009,16(9):1148-1152.
[17] Weintraub M,Koester J,Potenza MN,et al.Impulse control disorders in Parkinson disease:a cross-sectional study of 3090 patients[J].Arch Neurol,2010,67(5):589-595.
[18] Ramirez-Zamora A,Gee L,Boyd J,et al.Treatment of impulse control disorders in Parkinson's disease:Practical considerations and future directions[J].Expert Rev Neurother,2016,16(4):389-399.
[19] Cataln MJ,De Pablo-Fernndez E,Villanueva C,et al.Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease[J].Mov Disord,2013,28(14):2007-2010.